Cardio Diagnostics (CDIO) Competitors

Cardio Diagnostics logo
$1.60 -0.05 (-3.03%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.60 -0.01 (-0.31%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CDIO vs. EDSA, ATOS, KTTA, APLT, and AKTX

Should you buy Cardio Diagnostics stock or one of its competitors? Cardio Diagnostics's main competitors and comparable companies include Edesa Biotech (EDSA), Atossa Genetics (ATOS), Pasithea Therapeutics (KTTA), Applied Therapeutics (APLT), and Akari Therapeutics (AKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cardio Diagnostics compare to Edesa Biotech?

Cardio Diagnostics (NASDAQ:CDIO) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardio Diagnostics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Edesa Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

Cardio Diagnostics has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Cardio Diagnostics has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$10K473.60-$6.50M-$2.53N/A
Edesa BiotechN/AN/A-$7.19M-$1.69N/A

Edesa Biotech has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,543.75%. Cardio Diagnostics' return on equity of -89.41% beat Edesa Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardio Diagnostics-40,543.75% -89.41% -82.81%
Edesa Biotech N/A -560.22%-105.74%

In the previous week, Edesa Biotech had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Edesa Biotech and 1 mentions for Cardio Diagnostics. Edesa Biotech's average media sentiment score of 0.79 beat Cardio Diagnostics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardio Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Edesa Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cardio Diagnostics and Edesa Biotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Cardio Diagnostics compare to Atossa Genetics?

Cardio Diagnostics (NASDAQ:CDIO) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 9.8% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Atossa Genetics has a consensus target price of $20.33, suggesting a potential upside of 1,170.83%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Atossa Genetics is more favorable than Cardio Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardio Diagnostics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Atossa Genetics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Cardio Diagnostics has higher revenue and earnings than Atossa Genetics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$10K473.60-$6.50M-$2.53N/A
Atossa GeneticsN/AN/A-$34.77M-$2.62N/A

Cardio Diagnostics has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Atossa Genetics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,543.75%. Cardio Diagnostics' return on equity of -89.41% beat Atossa Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardio Diagnostics-40,543.75% -89.41% -82.81%
Atossa Genetics N/A -117.07%-96.08%

In the previous week, Cardio Diagnostics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 1 mentions for Cardio Diagnostics and 0 mentions for Atossa Genetics. Cardio Diagnostics' average media sentiment score of 0.00 equaled Atossa Genetics'average media sentiment score.

Company Overall Sentiment
Cardio Diagnostics Neutral
Atossa Genetics Neutral

Summary

Cardio Diagnostics and Atossa Genetics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cardio Diagnostics compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.5% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cardio Diagnostics has higher revenue and earnings than Pasithea Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/A-$20.43M-$1.37N/A
Cardio Diagnostics$10K473.60-$6.50M-$2.53N/A

Pasithea Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,543.75%. Pasithea Therapeutics' return on equity of -48.79% beat Cardio Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A -48.79% -46.24%
Cardio Diagnostics -40,543.75%-89.41%-82.81%

In the previous week, Cardio Diagnostics had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for Cardio Diagnostics and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company Overall Sentiment
Pasithea Therapeutics Neutral
Cardio Diagnostics Neutral

Pasithea Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 532.91%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Pasithea Therapeutics is more favorable than Cardio Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pasithea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cardio Diagnostics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Pasithea Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market.

Summary

Pasithea Therapeutics beats Cardio Diagnostics on 9 of the 14 factors compared between the two stocks.

How does Cardio Diagnostics compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market.

In the previous week, Applied Therapeutics and Applied Therapeutics both had 1 articles in the media. Applied Therapeutics' average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Applied Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cardio Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Applied Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,543.75%. Cardio Diagnostics' return on equity of -89.41% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied TherapeuticsN/A -340.84% -175.00%
Cardio Diagnostics -40,543.75%-89.41%-82.81%

Cardio Diagnostics has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A
Cardio Diagnostics$10K473.60-$6.50M-$2.53N/A

Applied Therapeutics presently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Applied Therapeutics is more favorable than Cardio Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Cardio Diagnostics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cardio Diagnostics beats Applied Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cardio Diagnostics compare to Akari Therapeutics?

Cardio Diagnostics (NASDAQ:CDIO) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Cardio Diagnostics has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Akari Therapeutics has a consensus target price of $32.33, suggesting a potential upside of 350.32%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than Cardio Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardio Diagnostics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, Akari Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Akari Therapeutics and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardio Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cardio Diagnostics has higher revenue and earnings than Akari Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$10K473.60-$6.50M-$2.53N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 30.0% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Akari Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,543.75%. Cardio Diagnostics' return on equity of -89.41% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardio Diagnostics-40,543.75% -89.41% -82.81%
Akari Therapeutics N/A -149.24%-74.92%

Summary

Akari Therapeutics beats Cardio Diagnostics on 8 of the 13 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDIO vs. The Competition

MetricCardio DiagnosticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4.74M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.60%
P/E Ratio-0.6323.0732.5628.68
Price / Sales311.8914.847.815.19
Price / CashN/A21.9220.2520.77
Price / Book0.834.124.343.51
Net Income-$6.50M-$24.08M$3.51B$394.12M
7 Day Performance-15.34%-9.85%-8.07%-8.97%
1 Month Performance-6.16%-12.77%-10.29%-11.61%
1 Year Performance-38.34%-7.99%-4.70%-11.21%

Cardio Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDIO
Cardio Diagnostics
0.2228 of 5 stars
$1.60
-3.0%
N/A-38.3%$4.74M$15.19KN/A17
EDSA
Edesa Biotech
1.3052 of 5 stars
$2.04
+3.8%
N/A+19.1%$19.62MN/AN/A17
ATOS
Atossa Genetics
2.2923 of 5 stars
$1.89
-0.5%
$20.33
+975.3%
-86.3%$18.87MN/AN/A14
KTTA
Pasithea Therapeutics
1.8892 of 5 stars
$0.49
+13.7%
$3.00
+507.3%
+62.2%$18.15MN/AN/A5
APLT
Applied Therapeutics
1.3171 of 5 stars
$0.10
flat
$1.00
+870.9%
N/A$15.86M$1MN/A30

Related Companies and Tools


This page (NASDAQ:CDIO) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners